Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide (Q84617955)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide (English)

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

13 June 2024

1 reference

Christoph Kapitza

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Milan Zdravkovic

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Eric Zijlstra

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Stine Segel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Tim Heise

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Anne Flint

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20671294

13 June 2024

publication date

29 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

8 February 2020

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1177%2F0091270010374474

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

http://onlinelibrary.wiley.com/wol1/doi/10.1177/0091270010374474/fullpdf

13 June 2024

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

The Journal of Clinical Pharmacology

13 June 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

951-955

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

Glucagon-like peptide-1 7-36: a physiological incretin in man.

8 February 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

13 June 2024

2

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Glucagonlike peptide 1: a newly discovered gastrointestinal hormone

13 June 2024

3

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

13 June 2024

4

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

13 June 2024

5

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

13 June 2024

6

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

13 June 2024

7

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

13 June 2024

8

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

13 June 2024

9

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

13 June 2024

10

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

13 June 2024

11

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

13 June 2024

12

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

13 June 2024

13

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Absorption of rapid-acting insulin in obese and nonobese NIDDM patients

13 June 2024

15

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Intraregional differences in the absorption of unmodified insulin from the abdominal wall

13 June 2024

16

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry

13 June 2024

17

1 reference

https://api.crossref.org/works/10.1177/0091270010374474

13 June 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20671294%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference